ABSTRACT
Objective:To study the correlation of p53、cerbB-2 expression in breast cancer with the clinical response to TE regimen neoadjuvant chemotherapy,and search for biological markers to guide therapy and predict effect of neoadjuvant chemotherapy. Methods:The expression of the p53,cerbB-2 was examined by immunohistoehemical assay in samples of breast cancer tissue before neoadjuvant chemotherapy which taken from 57 case of breast cancer patients.Results:The overall response rate to neoadjuvant chemotherapy was 73.7%.The effect of neoadjuvant chemotherapy was not related to types of tumor and TNM stage. The effect of neoadjuvant chemotherapy had a significantly negative correlation with p53 expression. There was no significant diference between the response to neoadjuvant chemotherapy and cerbB-2 expression.Of the 11 patients who obtained a complete clinical response,Only one was classified as p53 positive(P
